Merck and Orion collaborate for the development and commercialization of ODM-208

Orion to receive an upfront payment of USD 290 million

Healthcare Triangle closes $6.5 million private placement

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.

Healthcare Triangle announces $6.5 million private placement

Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions

Revelation Pharma completes 8th acquisition

Wedgewood Pharmacy operates compounding pharmacies that offers sterile and non-sterile compounded medications for animal patients in 50 states.

LG Chem’s new drug for obesity receives additional orphan drug designation by US FDA

With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development

Eurocine Vaccines expands portfolio with a therapeutic HSV-2 vaccine candidate

Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.

Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies

During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.

Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod

Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis